Alcohol-related liver disease

Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)

Juan P. Arab, Juan P. Roblero, Jose Altamirano, Fernando Bessone, Roberta Chaves Araujo, Fatima Higuera-De la Tijera, Juan Carlos Restrepo, Aldo Torre, Alvaro Urzua, Douglas Simonetto, Juan G. Abraldes, Nahum Méndez-Sánchez, Fernando Contreras, Michael R. Lucey, Vijay Shah, Helena Cortez-Pinto, Ramon Bataller

Research output: Contribution to journalReview article

Abstract

Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy.

Original languageEnglish (US)
Pages (from-to)518-535
Number of pages18
JournalAnnals of hepatology
Volume18
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Practice Guidelines
Liver Diseases
Alcohols
Liver
Alcoholic Hepatitis
Latin America
Therapeutics
Alcoholic Liver Cirrhosis
Acetylcysteine
Granulocyte Colony-Stimulating Factor
Fatty Liver
Public Policy
Health Policy
Prednisolone
Jaundice
Alcohol Drinking
Liver Transplantation
Alcoholism
Hepatocellular Carcinoma
Chronic Disease

Keywords

  • Alcohol
  • Alcohol use disorder
  • Alcohol-related liver disease
  • Alcoholic hepatitis
  • Alcoholic liver disease
  • Cirrhosis
  • Clinical practice guidelines
  • Corticosteroids

ASJC Scopus subject areas

  • Hepatology

Cite this

Arab, J. P., Roblero, J. P., Altamirano, J., Bessone, F., Chaves Araujo, R., Higuera-De la Tijera, F., ... Bataller, R. (2019). Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Annals of hepatology, 18(3), 518-535. https://doi.org/10.1016/j.aohep.2019.04.005

Alcohol-related liver disease : Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). / Arab, Juan P.; Roblero, Juan P.; Altamirano, Jose; Bessone, Fernando; Chaves Araujo, Roberta; Higuera-De la Tijera, Fatima; Restrepo, Juan Carlos; Torre, Aldo; Urzua, Alvaro; Simonetto, Douglas; Abraldes, Juan G.; Méndez-Sánchez, Nahum; Contreras, Fernando; Lucey, Michael R.; Shah, Vijay; Cortez-Pinto, Helena; Bataller, Ramon.

In: Annals of hepatology, Vol. 18, No. 3, 01.05.2019, p. 518-535.

Research output: Contribution to journalReview article

Arab, JP, Roblero, JP, Altamirano, J, Bessone, F, Chaves Araujo, R, Higuera-De la Tijera, F, Restrepo, JC, Torre, A, Urzua, A, Simonetto, D, Abraldes, JG, Méndez-Sánchez, N, Contreras, F, Lucey, MR, Shah, V, Cortez-Pinto, H & Bataller, R 2019, 'Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)', Annals of hepatology, vol. 18, no. 3, pp. 518-535. https://doi.org/10.1016/j.aohep.2019.04.005
Arab, Juan P. ; Roblero, Juan P. ; Altamirano, Jose ; Bessone, Fernando ; Chaves Araujo, Roberta ; Higuera-De la Tijera, Fatima ; Restrepo, Juan Carlos ; Torre, Aldo ; Urzua, Alvaro ; Simonetto, Douglas ; Abraldes, Juan G. ; Méndez-Sánchez, Nahum ; Contreras, Fernando ; Lucey, Michael R. ; Shah, Vijay ; Cortez-Pinto, Helena ; Bataller, Ramon. / Alcohol-related liver disease : Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). In: Annals of hepatology. 2019 ; Vol. 18, No. 3. pp. 518-535.
@article{d1b3ca2be944499492110e5790982a26,
title = "Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)",
abstract = "Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy.",
keywords = "Alcohol, Alcohol use disorder, Alcohol-related liver disease, Alcoholic hepatitis, Alcoholic liver disease, Cirrhosis, Clinical practice guidelines, Corticosteroids",
author = "Arab, {Juan P.} and Roblero, {Juan P.} and Jose Altamirano and Fernando Bessone and {Chaves Araujo}, Roberta and {Higuera-De la Tijera}, Fatima and Restrepo, {Juan Carlos} and Aldo Torre and Alvaro Urzua and Douglas Simonetto and Abraldes, {Juan G.} and Nahum M{\'e}ndez-S{\'a}nchez and Fernando Contreras and Lucey, {Michael R.} and Vijay Shah and Helena Cortez-Pinto and Ramon Bataller",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.aohep.2019.04.005",
language = "English (US)",
volume = "18",
pages = "518--535",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "3",

}

TY - JOUR

T1 - Alcohol-related liver disease

T2 - Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)

AU - Arab, Juan P.

AU - Roblero, Juan P.

AU - Altamirano, Jose

AU - Bessone, Fernando

AU - Chaves Araujo, Roberta

AU - Higuera-De la Tijera, Fatima

AU - Restrepo, Juan Carlos

AU - Torre, Aldo

AU - Urzua, Alvaro

AU - Simonetto, Douglas

AU - Abraldes, Juan G.

AU - Méndez-Sánchez, Nahum

AU - Contreras, Fernando

AU - Lucey, Michael R.

AU - Shah, Vijay

AU - Cortez-Pinto, Helena

AU - Bataller, Ramon

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy.

AB - Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy.

KW - Alcohol

KW - Alcohol use disorder

KW - Alcohol-related liver disease

KW - Alcoholic hepatitis

KW - Alcoholic liver disease

KW - Cirrhosis

KW - Clinical practice guidelines

KW - Corticosteroids

UR - http://www.scopus.com/inward/record.url?scp=85066919836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066919836&partnerID=8YFLogxK

U2 - 10.1016/j.aohep.2019.04.005

DO - 10.1016/j.aohep.2019.04.005

M3 - Review article

VL - 18

SP - 518

EP - 535

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 3

ER -